StockStory Backs Genpact (G) While Warning on Central Garden (CENT) and Corcept (CORT) Valuations

Independent research firm StockStory highlighted Genpact (NYSE:G) as the strongest buy among three Wall Street favorites, while questioning the rich valuations of Central Garden & Pet (NASDAQ:CENT) and Corcept Therapeutics (NASDAQ:CORT) despite analyst price targets suggesting over 20% upside. Consensus targets for CENT, CORT, and G imply returns of 24.7%, 29.7%, and 28.6%, respectively, from their June 1, 2026 closing prices. However, StockStory cautioned that such forecasts often reflect investment banking conflicts rather than genuine value. Genpact, trading at $33.00 per share and a forward P/E of 7.8x, presents an attractive entry based on its digital transformation and AI services. In contrast, Central Garden’s 13x forward multiple and Corcept’s 57.6x forward multiple raised valuation concerns, damping enthusiasm even as both companies show operational strength.